Redefining the primary objective of phase I oncology trials

1 December 2014 0

Cytotoxic agents are conventionally dosed on the basis of the maximum tolerated dose defined in phase I trials. A study assessing adverse events in over 2,000 patients treated with molecularly targeted agents suggests a need [more]

Cytotoxic agents are conventionally dosed on the basis of the maximum tolerated dose defined in phase I trials. A study assessing adverse events in over 2,000 patients treated with molecularly targeted agents suggests a need to...... [ more ]

Struck by cancer, killed by ageism

1 March 2013 0

Care of elderly cancer patients has improved over recent years; however, younger patients in Europe still survive longer than more elderly patients, and the difference cannot be accounted for by the higher likelihood of dying [more]

Care of elderly cancer patients has improved over recent years; however, younger patients in Europe still survive longer than more elderly patients, and the difference cannot be accounted for by the higher likelihood of dying from... [ more ]

Richard Sullivan: Why are we doing this?

1 March 2013 0

Cancer policy is determined by opinions not evidence, with the loudest voice setting the agenda. This is the worry of Richard Sullivan, who is on a mission to open the discussion to voices beyond the [more]

Cancer policy is determined by opinions not evidence, with the loudest voice setting the agenda. This is the worry of Richard Sullivan, who is on a mission to open the discussion to voices beyond the “comfortable little world of..... [ more ]

We hit the spot

1 March 2013 0

Less invasive than surgery and less toxic than systemic therapy, will the fast-growing specialty of interventional radiology join the ‘big three’ as the fourth pillar of cancer care? Looking at the specialists in the front-line [more]

Less invasive than surgery and less toxic than systemic therapy, will the fast-growing specialty of interventional radiology join the ‘big three' as the fourth pillar of cancer care?... [ more ]

Centralising cancer services: is this the best way to improve results?

1 March 2013 0

Is the centralisation of cancer services justified? Could many cancers be treated more locally without compromising safety? Cancer World’s Anna Wagstaff posed this question to two experts: Susan O’Reilly and Renée Otter. In an effort [more]

Is the centralisation of cancer services justified? Could many cancers be treated more locally without compromising safety? Cancer World's Anna Wagstaff posed this question to two experts: Susan O'Reilly and Renée Otter.... [ more ]

Tobacco tactics in the headlines

1 March 2013 0

At a time when the British media has been under the spotlight for its for poor ethical standards, The Independent’s Big Tobacco Exposed series shows why good investigative journalism remains so important in opening powerful [more]

At a time when the British media has been under the spotlight for its for poor ethical standards, The Independent's Big Tobacco Exposed series shows why good investigative journalism remains so important in opening powerful bodies... [ more ]

Skin toxicities caused by targeted therapies

1 March 2013 0

Targeted drugs can result in a variety of skin toxicities that are unpleasant for patients and, if unattended to, can lead them to stop taking their drug as prescribed. Effective teamwork is required to ensure [more]

Targeted drugs can result in a variety of skin toxicities that are unpleasant for patients and, if unattended to, can lead them to stop taking their drug as prescribed. Effective teamwork is required to ensure symptoms are...... [ more ]

Is there an app for that?

1 March 2013 0

Smartphones give patients the technology not only to record a consultation but also to share it privately, post it on a social network or even upload it to a public website. What does this mean [more]

Smartphones give patients the technology not only to record a consultation but also to share it privately, post it on a social network or even upload it to a public website. What does this mean for doctors and their relationship..... [ more ]

Aprepitant and control of emesis induced by five-day chemotherapy

1 March 2013 0

Addition of aprepitant, an NK-1 receptor antagonist, to dexamethasone and a 5-HT3 receptor antagonist contributes substantially to emetic control in patients receiving five-day cisplatin-containing chemotherapy, a new trial shows. Some needs in antiemetic therapy remain [more]

Addition of aprepitant, an NK-1 receptor antagonist, to dexamethasone and a 5-HT3 receptor antagonist contributes substantially to emetic control in patients receiving five-day cisplatin-containing chemotherapy, a new trial shows.... [ more ]

My World – Jacob Scott

1 March 2013 0

My World Jacob Scott uses approaches from his previous life as a physicist and engineer to build models of cancer biology and evolution from first principles, in the hope of generating novel, translatable hypotheses. On [more]

My world... [ more ]